Evidence map›Paper›PMID 36332528›Full record

ArticleJournal of substance abuse treatment2023

Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.

Colby J Hyland, Michal J McDowell, Paul A Bain, Haiden A Huskamp, Alisa B Busch

Open access · greenAbstract readScoping Review
In one paragraph

Article in Journal of substance abuse treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Impact of Multisite Patient Education on Pharmacotherapy for Veterans With Alcohol Use Disorder.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Colby J HylandHarvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States of America. Electronic address: colby_hyland@hms.harvard.edu.
Michal J McDowellDepartment of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, United States of America.
Paul A BainCountway Library of Medicine, Harvard Medical School, 10 Shattuck Street, Boston, MA 02115, United States of America. Electronic address: paul_bain@hms.harvard.edu.
Haiden A HuskampDepartment of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, United States of America. Electronic address: huskamp@hcp.med.harvard.edu.
Alisa B BuschDepartment of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, United States of America; McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, United States of America. Electronic address: abusch@mclean.harvard.edu.
Harvard University · USMassachusetts General Hospital · USMcLean Hospital · US

Funding

Research Support CoreP30DA035772 · NIDA · BRANDEIS UNIVERSITY · PI Haiden A Huskamp, SHARON REIF · 2015 to 2026
$11.3M
Fostering Research Mentorship & Training during Psychiatry Residency SupplementR25MH094612 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI FAVA, MAURIZIO, GREENFIELD, SHELLY F. · 2011 to 2022
$2.3M
NIDA NIH HHS P30 DA035772NIMH NIH HHS R25 MH094612
6 · The paper itself

Abstract

backgroundAlcohol use disorder (AUD) represents the most prevalent addiction in the United States. Integration of AUD treatment in primary care settings would expand care access. The objective of this scoping review is to examine models of AUD treatment in primary care that include pharmacotherapy (acamprosate, disulfiram, naltrexone).

methodsThe team undertook a search across MEDLINE, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, and Web of Science on May 21, 2021. Eligibility criteria included: patient population ≥ 18 years old, primary care-based setting, US-based study, presence of an intervention to promote AUD treatment, and prescription of FDA-approved AUD pharmacotherapy. Study design was limited to controlled trials and observational studies. We assessed study bias using a modified Oxford Centre for Evidence-based Medicine Rating Framework quality rating scheme.

resultsThe qualitative synthesis included forty-seven papers, representing 25 primary studies. Primary study sample sizes ranged from 24 to 830,825 participants and many (44 %) were randomized controlled trials. Most studies (80 %) included a nonpharmacologic intervention for AUD: 56 % with brief intervention, 40 % with motivational interviewing, and 12 % with motivational enhancement therapy. A plurality of studies (48 %) included mixed pharmacologic interventions, with administration of any combination of naltrexone, acamprosate, and/or disulfiram. Of the 47 total studies included, 68 % assessed care initiation and engagement. Fewer studies (15 %) explored practices surrounding screening for or diagnosing AUD. Outcome measures included receipt of pharmacotherapy and alcohol consumption, which about half of studies included (53 % and 51 %, respectively). Many of these outcomes showed significant findings in favor of integrated care models for AUD.

conclusionsThe integration of AUD pharmacotherapy in primary care settings may be associated with improved process and outcome measures of care. Future research should seek to understand the varied experiences across care integration models.

Indexed as

AlcoholismAcamprosateAdolescentAlcohol DrinkingDisulfiramHumansNaltrexonePrimary Health CareRandomized Controlled Trials as TopicUnited StatesAcamprosateDisulfiramNaltrexoneAlcohol use disorderIntegrated careNaltrexonePharmacotherapyPrimary care

Identifiers

PMID36332528
PMCPMC10321472
OpenAlexW4308150966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.